Petmed Stock News

Invesco Ltd. lowered its stake in PetMed Express, Inc. (NASDAQ:PETS) by 0.8% during the second quarter, HoldingsChannel reports. The firm owned 113,897 shares of the companys stock after selling 930 shares during the quarter. Invesco Ltd.s holdings in PetMed Express were worth $3,627,000 as of its most recent filing with the Securities and Exchange Commission. []

Comerica Bank lessened its holdings in shares of PetMed Express, Inc. (NASDAQ:PETS) by 7.7% in the second quarter, Holdings Channel.com reports. The fund owned 18,954 shares of the companys stock after selling 1,582 shares during the quarter. Comerica Banks holdings in PetMed Express were worth $514,000 at the end of the most recent quarter. A []

PetMed Express (NASDAQ:PETS) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zacks, PetMed Express, Inc. and subsidiaries, d/b/a 1-800-PetMeds (the Company), is a leading nationwide pet pharmacy. The Company markets prescription and non-prescription pet medications, health products, []

Morgan Stanley grew its position in PetMed Express, Inc. (NASDAQ:PETS) by 19.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 311,228 shares of the companys stock after acquiring an additional 50,009 shares during the period. Morgan Stanley owned about 1.53% of PetMed Express worth []

Prudential Financial Inc. trimmed its holdings in shares of PetMed Express, Inc. (NASDAQ:PETS) by 9.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,584 shares of the companys stock after selling 2,361 shares during the quarter. Prudential Financial Inc. []

PetMed Express Inc. (NASDAQ:PETS)s traded shares stood at 0.34 million during the last session, with the companys beta value hitting 0.53. At the close of trading, the stocks price was $29.43, to imply a decrease of -0.20% or -$0.06 in intraday trading. The PETS shares 52-week high remains $57.00, putting it -93.68% down since that PetMed Express Inc. At $29.43: Buy, Sell Or Hold? Read More »

Shares of PetMed Express, Inc. (NASDAQ:PETS) fell 6.4% on Thursday . The stock traded as low as $28.19 and last traded at $28.19. 572 shares were traded during mid-day trading, a decline of 100% from the average session volume of 627,445 shares. The stock had previously closed at $30.12. PETS has been the subject of []

PetMed Express, Inc. (NASDAQ:PETS) dropped 6.4% on Thursday . The stock traded as low as $28.19 and last traded at $28.19. Approximately 572 shares changed hands during trading, a decline of 100% from the average daily volume of 627,445 shares. The stock had previously closed at $30.12. PETS has been the subject of several recent []

Profit Investment Management LLC lessened its stake in PetMed Express, Inc. (NASDAQ:PETS) by 71.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 27,689 shares of the companys stock after selling 70,959 shares during the quarter. Profit Investment Management LLCs holdings []

Schonfeld Strategic Advisors LLC purchased a new stake in shares of PetMed Express, Inc. (NASDAQ:PETS) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 6,996 shares of the companys stock, valued at approximately $223,000. A number of other hedge funds and other institutional investors also recently bought and sold shares of PETS. Rockefeller Capital []

Freshpet is the latest pet industry stock to fall short of Wall Street expectations. Who let the dogs out?

Another miss for the pet wellness stock finds it scrambling for a new growth driver.

PetMed Express Inc (NASDAQ: PETS) reported a Q2 EPS of $0.31, missing the consensus of $0.34 and lower than $0.42 posted a year ago. Net sales were $67.4 million, down 10.7% Y/Y and far below the c

PetMed Express, Inc. (PETS) CEO Matt Hulett on Q2 2022 Results - Earnings Call Transcript

These investments seem pretty vulnerable right now.